In this roundtable interview series, we speak to each of the organizers of the CannMed Medical Practicum to learn more about them and what attends can expect from the practicum. Here in part I, they share some of the clinical applications for medical cannabis and dosing information.
Founded in 2016 by Medicinal Genomics, the upcoming CannMed conference—taking place September 29–October 1 in Pasadena, California—will feature an exciting full-day CannMed Medical Practicum organized by Bonni Goldstein, MD, (the practicum’s originator); Dustin Sulak, DO; Kevin Spelman, PhD, MCPP; and Eloise Theisen, RN, MSN, AGPCNP-BC. During this practicum, each of the presenters will share the latest research, their clinical experience, and practice guidelines related to cannabinoid therapeutics, inclusive of types of extractions, products, and optimal dosing of cannabinoids for various therapeutic scenarios. This course is approved by the California Board of Registered Nursing for 9.5 contact hours.**
In this roundtable interview series, we speak to each of the organizers to learn more about them and what attendees can expect from the practicum. Here in part I, they share some of the clinical applications for medical cannabis and dosing information.
Bonni Goldstein, MD: Medical cannabis can be useful for numerous conditions, including managing symptoms of neurodegenerative disorders, inflammatory gastrointestinal conditions, symptoms from cancer and cancer treatment, chronic pain, sleep disorders, and some psychiatric disorders. Because of the widespread distribution of the cannabinoid receptor, we know that the endocannabinoid system plays a role in almost every physiologic process and therefore can be utilized as a target for treatment.
Kevin Spelman, PhD, MCPP: Anxiety, seizure disorders, pain, mood disorders, sleep issues, and autoimmune disorders.
Dustin Sulak, DO: Chronic pain, insomnia, PTSD, nausea, and vomiting are certainly the most common, but a typical cannabis practice is full of refractory conditions from every other field in medicine, for example, psychiatry, gastroenterology, oncology, neurology, rheumatology, and so forth. Overall, cannabis is often an effective treatment when everything else has failed.
Eloise Theisen, RN, MSN, AGPCNP-BC: According to the National Academies of Sciences, Engineering and Medicine report on the health effects of cannabis and cannabiniods, there is moderate to substantial evidence to support the use of cannabis for chronic pain in adults, sleep disorders, chemotherapy induced nausea and vomiting, and muscle spasms in multiple sclerosis. Additionally, we are seeing more clinical data to support the use of cannabinoids for anxiety, depression, and PTSD.
Bonni Goldstein, MD: Medical cannabis is different than most pharmaceutical medications, meaning there are no specific dosing recommendations for the vast majority of conditions being treated. Patients are advised to “start low and go slow” to customize their dosing regimen. The reasons for this include a wide inter-individual variation in absorption, metabolism, and excretion of the cannabinoids and other compounds in the plant. However, a clinician knowledgeable in cannabis dosing can help a patient negotiate dosing for the many products on the market, helping to personalize the patient’s dosing regimen. Methods of use include inhalation, ingestion, sublingual, topical and transdermal applications. Each of these has advantages and disadvantages that can help patients choose their preferred method, although many patients use multiple methods of use depending on symptoms, time of day and cost.
Kevin Spelman, PhD, MCPP: Dosing has a high interindividual variability. Best to start at very low doses and work up so the optimal "physiological" dose can be found (versus a "pharmacological" dose)
Dustin Sulak, DO: Cannabis is highly versatile and allows for individualized treatments that can often be fine-tuned to allow for all benefit and no adverse side effects. This fine-tuning includes delivery methods (oral, oromucosal, inhaled, topical), numerous varieties of cannabis with distinct properties. You can find more info at: https://healer.com/using-medical-cannabis-delivery-systems/
Eloise Theisen, RN, MSN, AGPCNP-BC: Cannabis is best when it is individualized to the patient's condition and goals of care. It is important to take a thorough health history and discuss the plan of care with the patient. Some patients may need low doses to achieve relief and others may need higher doses and that usually cannot be determined without considering many factors like age, gender, other health conditions, medications and previous or current cannabis experience. In some cases, patients may need multiple methods of administration to effectively treat their condition.
Check back next month for part II of this series where our roundtable will discuss the role medical cannabis can play in stopping opioid addiction and how it might interact with other medications. To find out more about the CannMed Medical Practicum, please visit: https://cannmedevents.com/practicum/
**CONTINUING EDUCATION CREDITS: This course is provider-approved by the California Board of Registered Nursing, provider number 16845, for 9.5 contact hours.
Bonni Goldstein, MD, is the owner and medical director of Canna-Centers Wellness and Education, a medical practice devoted to educating patients about the use of cannabis for serious and chronic medical conditions. Dr. Goldstein was a Clinical Instructor in Pediatrics at USC School of Medicine in Los Angeles, Emergency Transport Attending Physician at Childrens Hospital Los Angeles, and Emergency Medicine Attending Physician in the Pediatric Emergency Department at Los Angeles County-USC Medical Center. A frequent speaker nationally and internationally, Dr. Goldstein was awarded “2017 Healthcare Professional of the Year” by Americans for Safe Access, a non-profit that promotes safe and legal access to cannabis throughout the nation. She is on the board of the International Association for Cannabis as Medicine and is also on the Medical Advisory board of Whole Plant Access for Autism, a non-profit that provides education and resources to families of individuals with autism. Dr. Goldstein’s first book, Cannabis Revealed, was awarded “2017 Semifinalist Book of the Year” by the American Botanical Council. Her latest book, Cannabis is Medicine, was published by Little, Brown Spark in September 2020. She is the medical advisor to Weedmaps.com.
Kevin Spelman, PhD, MCPP is a researcher, clinician, educator and industry consultant that has advised the White House and the Department of Defense on natural products for regulatory guidelines and research on effective battlefield hemostatics, respectively. Dr. Spelman studied brain cancer, as well as CB1 and CB2 receptor binding as a Postdoctoral Fellow at National Institutes of Health and was the first researcher to elucidate cannabinoid ligands in Zanthoxylum spp. He has also carried out malaria and natural products research as a Marie Curie Research Fellow in the European Union and has focused on molecular techniques to elucidate the pharmacology of phytochemicals on human physiology and has 27 peer reviewed publications on medicinal plants. He has also been a senior R&D executive for multiple companies over the last decade. Dr. Spelman has considerable experience in medicinal plant, nutraceutical and cannabinoid research and has coordinated new product development, analytical and QC guidelines, research activity and educational curriculums for industry and universities over the last 30 years.
Dustin Sulak, DO
Dr. Dustin Sulak is an osteopathic general practitioner whose clinical practice focuses on treating refractory conditions in adults and children with an individualized, health-centered approach. Dr. Sulak received undergraduate degrees in nutrition science and biology from Indiana University, a doctorate of osteopathy from the Arizona College of Osteopathic Medicine, and completed an osteopathic rotating internship at Maine-Dartmouth Family Medicine Residency. Dr. Sulak is a founder of Integr8 Health, a medical practice in Maine that follows over 8,000 patients using medical cannabis, a cofounder of Healer.com, a medical cannabis education resource, and serves on the board of directors of two non-profits, the Society of Cannabis Clinicians and Patients Out of Time.
Eloise Theisen, RN, MSN, AGPCNP-BC
Eloise Theisen is a board certified Adult Geriatric Nurse Practitioner who specializes in cannabis therapy. For over 20 years, Eloise has worked primarily with cancer, dementia and chronic pain patients. In the last 6 years, Eloise has focused her efforts on cannabinoid therapies. Since then she has worked with over 6000 patients to help them effectively treat age-related and chronic illness with cannabis. Eloise is a co-founder and the Chief Executive Officer of Radicle Health and Radicle Health Clinician Network. She is the current president of the American Cannabis Nurses Association (2020-2021) with over 1350 members nationally. Eloise also serves on the editorial board of the American Journal of Endocannabinoid Medicine, a journal dedicated to educating healthcare professionals on the subject of medical cannabis through research, independent medical studies and evidence based data. In 2019, Eloise co-wrote Pain Free with CBD: Everything you need to know to safely and effectively use cannabidiol. She is currently teaching the accredited medical cannabis certificate program at Pacific College of Health Sciences.
Collaboration, Gender Diversity, and Progress: Julie Kowalski on Advancing Cannabis Science
December 10th 2024In this interview with Cannabis Science and Technology, Julie Kowalski, an experienced analytical chemist, discusses her path into the cannabis industry, starting with early work in gas chromatography. Kowalski reflects on her perspectives as a female scientist, highlighting biases she’s experienced and the benefits of gender inclusivity in the cannabis space. Greater unity and professionalism could benefit the industry as a whole, she explains. She also encourages collaboration and more women in leadership positions in order to build a stronger scientific community, and also urges women to advocate for themselves, noting that women in cannabis face unique obstacles but often demonstrate consensus-building strategies and solutions.
Gender Diversity and Innovation in the Cannabis Space: Insights from Tess Eidem, PhD
December 9th 2024Cannabis Science and Technology sat down with Tess Eidem, PhD, PCQI, member of Saturn Scientific, LLC, to discuss her journey from antibiotic research to cannabis microbiology and her observations throughout her career. Dr. Eidem highlights challenges women face in this male-dominated industry, including limited representation in leadership roles and frequent experiences of bias and discrimination. She emphasizes the importance of gender diversity in fostering innovation, improving product safety, and addressing women’s health needs in cannabis applications. Her advice to women scientists is to build strong professional relationships and carefully evaluate work environments to advance their careers in this evolving and often challenging space.
Inside the University of Maryland School of Pharmacy’s Graduate Program in Medical Cannabis
September 16th 2024Leah Sera, PharmD, MA, the co-program director for the University of Maryland School of Pharmacy’s Graduate Studies in Medical Cannabis program sat down with Cannabis Science and Technology to discuss higher education in medical cannabis.
Studying the Evolution of Cannabis Education: Insights from Stockton University’s Course Instructors
September 13th 2024A leader in cannabis education in New Jersey, Stockton University offers a wide variety of courses to prepare its students to not only succeed in an ever-growing industry, but to also understand its complex history and shape its evolving future. Started six years ago, its Cannabis Studies Program continues its commitment to providing innovative and practical instruction to its students. Two influential figures in this space are Robert Mejia, Teaching Specialist in the Cannabis Studies Program, and Angela Speakman, Instructor in the Cannabis Studies Program. Here, they highlight the program’s practical approach to cannabis education, celebrate the success stories of graduates, discuss the National Cannabis Curriculum Convening, and address challenges in cannabis education and its role in the future.
Medical Cannabis Campaigning with Americans for Safe Access
September 4th 2024As discussions about the federal scheduling of cannabis continue, efforts by medical cannabis advocates are intensifying. One such advocate is Americans for Safe Access (ASA), a nonprofit organization founded by patients for patients. Since 2002, ASA has been championing the rights of medical cannabis patients and has recently launched new campaigns and strategies to refocus attention on patient needs. In this interview, Steph Sherer, founder and president of ASA, reflects on past successes in medical cannabis advocacy, shares her perspective on recent cannabis and hemp policymaking, and outlines the next steps for advancing a unified medical cannabis message on Capitol Hill—a message that could bring about the changes patients have long awaited.
Insights on Cannabis Testing Challenges and Industry Standards: An Interview with Douglas Duncan
August 9th 2024In light of recent headlines concerning cannabis laboratories throughout the country, Cannabis Science and Technology reached out to Douglas Duncan, Laboratory Director of Kairos Labs in Detroit, MI and member of our Editorial Advisory Board for more information. In this interview, Duncan shares his perspectives on lab shopping, major challenges in the industry today, and innovations in cannabis testing laboratories for the future. He also shares insights into consumer practices and the potential effects of a federal rescheduling of cannabis.